Galie N., Humbert M., Vachiery J.L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016. 37:67–119. https://doi.org/10.1183/13993003.01032-2015.
DOI: 10.1183/13993003.01032-2015

Benza R.L, Gomberg-Maitland M., Elliot C.G., et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison to ESC/ERS-based risk assessment strategies. Chest 2019; 156:323–337. https://doi.org/10.1016/j.chest.2019.02.004.
DOI: 10.1016/j.chest.2019.02.004

Sitbon O., Chin K.M., Channick R.N., et al. Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. J Heart Lung Transplant 2020; 39:300−309. https://doi.org/10.1016/j.healun.2019.12.013.
DOI: 10.1016/j.healun.2019.12.013

Sitbon, O. Pulmonary arterial hypertension: combination therapy in the modern management era. European respiratory review: an offcial journal of the European Respiratory Society vol. 19,118 (2010):348-9. doi:10.1183/09059180.00008310.
DOI: 10.1183/09059180.00008310

D’Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991; 115:343–349. https://doi.org/10.7326/0003-4819-115-5-343.
DOI: 10.7326/0003-4819-115-5-343

Chazova I, Martynyuk T, Valieva Z, et al. Clinical and instrumental characteristics of newly diagnosed patients with various forms of pulmonary hypertension according to the Russian National Registry. BioMed Research International 2020: Article ID 6836973. https://doi.org/10.1155/2020/6836973.
DOI: 10.1155/2020/6836973

Чазова И.Е., Мартынюк Т.В., Валиева З.С., соавт. Евразийские клинические рекомендации по диагностике и лечению легочной гипертензии. Евразийский кардиологический журнал 2020; 1:78-122. [Chazova I.E., Martynyuk T.V., Valieva Z.S., et al. Eurasian Guidelines for the diagnosis and treatment of pulmonary hypertension. Eurasian Нeart Journal 2020; 1:78-122. (In Russ.)] https://doi.org/10.38109/2225-1685-2020-1-78-122.
DOI: 10.38109/2225-1685-2020-1-78-122

Мартынюк Т.В. Легочная гипертензия: Диагностика и лечение. Сер. Библиотека ФГБУ «НМИЦ кардиологии» Минздрава России. — М.: ООО «Медицинское информационное агентство», 2018: 304 с. ISBN: 978-5-6040008-0-9. [Martynyuk T.V. Pulmonary hypertension: diagnosis and treatment. Moscow: LLC «Medical Information Agency», 2018: 304 р. ISBN:978-5-6040008-0-9. (In Russ.)]

Hoeper M.M., Kramer T., Pan Z., et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratifcation model. Eur Respir J 2017; 50:170740. https://doi.org/10.1183/13993003.00740-2017.
DOI: 10.1183/13993003.00740-2017

Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации. https://scardio.ru/content/Guidelines/2020/Clinic_rekom_LG.pdfhttps://scardio.ru/content/Guidelines/2020/Clinic_rekom_LG.pdf

Benza R.L, Miller D.P., Barst R.J., et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142:448–456. https://doi.org/10.1378/chest.11-1460.
DOI: 10.1378/chest.11-1460

Frost A.E., Badesch D.B., Miller D.P., et al. Evaluation of the predictive value of a clinical worsening defnition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest 2013; 144:1521–1529. https://doi.org/10.1378/chest.12-3023.
DOI: 10.1378/chest.12-3023

Kylhammar D., Kjellström B., Hjalmarsson C., et al. A comprehensive risk stratifcation at early follow-updetermines prognosis in pulmonary arterial hypertension. Eur Heart J 2018; 39(47):4175-4181. https://doi.org/10.1093/eurheartj/ehx257.
DOI: 10.1093/eurheartj/ehx257

Boucly A., Weatherald J., Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50: 170889. doi: 10.1183/13993003.00889-2017..
DOI: 10.1183/13993003.00889-2017

Sitbon O, Channick R, Chin MK, et al. Selexipag for the treatment of pulmonary arterial hypertension. The New England journal of medicine. 2015; vol. 373: 2522-33. https://doi.org/10.1056/NEJMoa1503184.
DOI: 10.1056/NEJMoa1503184

Мартынюк Т.В. Оценка приверженности пациентов с легочной гипертензией лечению ингаляционным илопростом (Вентавис): итоги проспективного многоцентрового неинтервенционного исследования IVENT. Системные гипертензии. 2019; 16(2):12-27. [Martynyuk T.V. Evaluation of compliance of pulmonary hypertension patients to the treatment with inhaled iloprost (Ventavis): results of prospective, multicenter, non-interventional IVENT study. Systemic Hypertension. 2019; 16(2):12-27 (In Russ.)] https://doi.org/10.26442/2075082X.2019.2.190352.
DOI: 10.26442/2075082X.2019.2.190352

Mubarak K.K. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010;104(1):9-21. https://doi.org/10.1016/j.rmed.2009.07.015.
DOI: 10.1016/j.rmed.2009.07.015

Gaine S., Sitbon O., Channick R.N. et al. Relationship between time from diagnosis and morbidity/mortality in pulmonary arterial hypertension: results from the phase III GRIPHON study. Pulmonary and Cardiovascular: Original Research. 2021; 160(1):277-286. https://doi.org/10.1016/j.chest.2021.01.066.
DOI: 10.1016/j.chest.2021.01.066

Валиева З.С., Мартынюк Т.В. Клинический случай успешного применения нового селективного агониста IP-рецепторов простациклина селексипаг у пациента с идиопатической легочной гипертензией. Евразийский кардиологический журнал. 2019; 25 (4): 144-149 [Trans. into Eng. ed.: Z.S. Valieva, T.V. Martynyuk. Case Report on the Successful Use of a New Selective Prostacyclin IP Receptor Agonist, Selexipag, in a Patient with Idiopathic Pulmonary Arterial Hypertension. Eurasian heart journal. 2019; 25 (4): 150-155], https://doi.org/10.38109/2225-1685-2019-4-144-155.
DOI: 10.38109/2225-1685-2019-4-144-155

Duggan ST, Keam SJ, Burness CB. Selexipag: A Review in Pulmonary Arterial Hypertension. Am J Cardiovasc Drugs. 2017;17(1):73-80. https://doi.org/10.1007/s40256-016-0209-9.
DOI: 10.1007/s40256-016-0209-9

Шмальц А.А., Горбачевский С.В. Возможности и ограничения для начальной комбинированной специфической терапии легочной артериальной гипертензии в Российской Федерации. Терапевтический архив. 2020; 92(12):80-85. [A.A. Shmalts, S.V. Gorbachevsky. Advantages and limitations of initial combination therapy in pulmonary arterial hypertensionpatients in Russia. Terapevticheskii arkhiv. 2020; 92(12):80-85 (In Russ.)] https://doi.org/10.26442/00403660.2020.12.000840.
DOI: 10.26442/00403660.2020.12.000840

Galiè N., Barberà J.A., Frost A.E., et al. Initial Use of Ambrisentan plus Tadalafl in Pulmonary Arterial Hypertension. N Engl J Med 2015; 373(9):834-44. https://doi.org/10.1056/NEJMoa1413687.
DOI: 10.1056/NEJMoa1413687

Chin KM, Sitbon O, Doelberg M, et al. Effcacy and Safety of Initial Triple Oral Versus Initial Double Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH): Results of the Randomized Controlled TRITON Study. American Thoracic Society. 2020; 201:A2928-A2928. https://doi.org/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928.
DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928

Kim NH, Hemnes AR, Chakinala MM, et al. Patient and disease characteristics of the frst 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. J Heart Lung Transplant. 2021 Apr; 40(4):279-288. https://doi.org/10.1016/j.healun.2021.01.006.
DOI: 10.1016/j.healun.2021.01.006

Chin K., Chakinala M., Hemnes A., et al. Real-world data for selexipag in patieants with connective tissue disease-associated pulmonary arterial hypertension: a SPHERE (selexipag: the users drug registry) analysis. CHEST, 2020; 158(4):A2187-A2190. https://doi.org/10.1016/j.chest.2020.08.1875.
DOI: 10.1016/j.chest.2020.08.1875

Kim N., Farber H.W., Highland K., et al. PCV3 Hospitalization Rates and Association with Survival Risk at Baseline in Patients with Pulmonary Artery Hypertension (PAH) Receiving Selexipag in Real-World (RW) Clinical Practice. Value in Health. 2020;23(2):S486, ISSN 1098-3015. https://doi.org/10.1016/j.jval.2020.08.494.
DOI: 10.1016/j.jval.2020.08.494

Lange T.J, Söderberg S., Biedermann P., et al. Selexipag Titration and Dosing Patterns in Patients with Pulmonary Arterial Hypertension (PAH) in a Real-World Clinical Setting: Insights from the EXPOSURE Study. Oral presentation at ATS 2021. Abstract A3607. https://doi.org/10.1164/ajrccmconference.2021.203.1_MeetingAbstracts.A3607.
DOI: 10.1164/ajrccmconference.2021.203.1_MeetingAbstracts.A3607

Barnikel M, Kneidinger N, Klenner F, et al. Real-life data on Selexipag for the treatment of pulmonary hypertension. Pulm Circ. 2019 Jan-Mar; 9(1):2045894019832199. https://doi.org/10.1177/2045894019832199.
DOI: 10.1177/2045894019832199

Galie N., Gaine S., Channick R. et al. Long-Term Survival, Safety and Tolerability with Selexipag in Advances in Therapy 2022; 39:796–810. https:// doi.org/10.1007/s12325-021-01898-1.
DOI: 10.1007/s12325-021-01898-1

Raina A, Abraham WT, Adamson PB, et al. Limitations of right heart catheterization in the diagnosis and risk stratifcation of patients with pulmonary hypertension related to left heart disease: insights from a wireless pulmonary artery pressure monitoring system. J Heart Lung Transplant. 2015 Mar; 34(3):438-47. https://doi.org/10.1016/j.healun.2015.01.983.
DOI: 10.1016/j.healun.2015.01.983

Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial [published correction appears in Lancet. 2012 Feb; 4;379(9814):412]. Lancet. 2011;377(9766):658-666. https://doi.org/10.1016/S0140-6736(11)60101-3.
DOI: 10.1016/S0140-6736(11)60101-3

Frantz RP, Benza RL, Kjellström B, et al. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2008; 27(7):780-788. https://doi.org/10.1016/j.healun.2008.04.009.
DOI: 10.1016/j.healun.2008.04.009

Мартынюк Т.В., Алеевская А.М., Родненков О.В., соавт. Ведение пациентов с легочной артериальной гипертензией в условиях пандемии новой коронавирусной инфекции. Евразийский кардиологический журнал 2020; 2: 54-60. [Martynyuk T.V., Aleevskaya A.M., Rodnenkov O.V., et al. Management of patients with pulmonary arterial hypertension in the pandemic of a new coronavirus infection. Eurasian Нeart Journal 2020; 2:54-60]. https://doi.org/10.38109/2225-1685-2020-2-54-60..
DOI: 10.38109/2225-1685-2020-2-54-60

Farha S. COVID-19 and pulmonary hypertension. Cleve Clin J Med 2020 May 11; ccc021. https://doi.org/10.3949/ccjm.87a.ccc021.
DOI: 10.3949/ccjm.87a.ccc021

Мартынюк Т.В., Чазова И.Е. Легочная артериальная гипертензия: достижения и реалии современного лечения, взгляд в будущее. Терапевтический архив. 2021; 93 (9):1009-1017. [Martynyuk T.V., Chazova I.E. Pulmonary arterial hypertension: achievements and realities of modern treatment, a look into the future. Terapevticheskii arkhiv. 2021; 93(9):1009-1017 (in Russ.)] https://doi.org/10.26442/00403660.2021.09.201013.
DOI: 10.26442/00403660.2021.09.201013